Literature DB >> 16173963

Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells.

Kihyun Kim1, Kyoungju Ryu, Younghyeh Ko, Chaehwa Park.   

Abstract

Natural killer/T-cell lymphoma (NKTL) is a highly aggressive disease. Despite the use of various treatment regimens, the prognosis of NKTL is poor, and new treatment strategies need to be determined. Because of the significant survival potential, nuclear factor (NF)-kappaB has become one of the major targets for drug development. In this study, we explored the effect and action mechanism of NF-kappaB inhibitors, BAY 11-7082 and curcumin, on NKTL cell lines (NKL, NK-92 and HANK1). Electrophoretic mobility shift assay showed that NF-kappaB was constitutively active in HANK1, a chemoresistant cell line. BAY 11-7082 and curcumin suppressed NF-kappaB activation in a time- and dose-dependent manner, which finally resulted in cell death. BAY 11-7082- and curcumin-induced cell death was associated with downregulation of Bcl-xL, cyclin D1, XIAP and c-FLIP, followed by caspase-8, poly(ADP-ribose) polymerase cleavage and activation. Given that the chemoresistant NK-92 cells respond to NF-kappaB inhibitors but not to conventional drugs, BAY 11-7082 and curcumin could be potentially useful for achieving improved outcome in chemotherapy-refractory NKTL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16173963     DOI: 10.1111/j.1365-2141.2005.05720.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Transforming growth factor-β downregulates sGC subunit expression in pulmonary artery smooth muscle cells via MEK and ERK signaling.

Authors:  Lili Du; Jesse D Roberts
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-09-27       Impact factor: 5.464

Review 2.  "Spicing up" of the immune system by curcumin.

Authors:  Ganesh Chandra Jagetia; Bharat B Aggarwal
Journal:  J Clin Immunol       Date:  2007-01-09       Impact factor: 8.317

Review 3.  New perspectives of curcumin in cancer prevention.

Authors:  Wungki Park; A R M Ruhul Amin; Zhuo Georgia Chen; Dong M Shin
Journal:  Cancer Prev Res (Phila)       Date:  2013-03-06

4.  Cancer-linked targets modulated by curcumin.

Authors:  Noor Hasima; Bharat B Aggarwal
Journal:  Int J Biochem Mol Biol       Date:  2012-12-24

5.  Properties of lewis lung carcinoma cells surviving curcumin toxicity.

Authors:  Dejun Yan; Michael E Geusz; Roudabeh J Jamasbi
Journal:  J Cancer       Date:  2011-12-22       Impact factor: 4.207

6.  Curcuminoids and ω-3 fatty acids with anti-oxidants potentiate cytotoxicity of natural killer cells against pancreatic ductal adenocarcinoma cells and inhibit interferon γ production.

Authors:  Ramesh C Halder; Anasheh Almasi; Bien Sagong; Jessica Leung; Anahid Jewett; Milan Fiala
Journal:  Front Physiol       Date:  2015-05-22       Impact factor: 4.566

Review 7.  Curcumin and tumor immune-editing: resurrecting the immune system.

Authors:  Sayantan Bose; Abir Kumar Panda; Shravanti Mukherjee; Gaurisankar Sa
Journal:  Cell Div       Date:  2015-10-12       Impact factor: 5.130

8.  PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.

Authors:  Xi-Wen Bi; Hua Wang; Wen-Wen Zhang; Jing-Hua Wang; Wen-Jian Liu; Zhong-Jun Xia; Hui-Qiang Huang; Wen-Qi Jiang; Yu-Jing Zhang; Liang Wang
Journal:  J Hematol Oncol       Date:  2016-10-13       Impact factor: 17.388

Review 9.  Ubc13: the Lys63 ubiquitin chain building machine.

Authors:  Curtis D Hodge; Leo Spyracopoulos; J N Mark Glover
Journal:  Oncotarget       Date:  2016-09-27

10.  The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system.

Authors:  Sam Strickson; David G Campbell; Christoph H Emmerich; Axel Knebel; Lorna Plater; Maria Stella Ritorto; Natalia Shpiro; Philip Cohen
Journal:  Biochem J       Date:  2013-05-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.